Role of renin-angiotensin system in liver diseases: an outline on the potential therapeutic points of intervention

Expert Rev Gastroenterol Hepatol. 2016 Nov;10(11):1279-1288. doi: 10.1080/17474124.2016.1207523. Epub 2016 Jul 14.

Abstract

The current review aimed to outline the functions of the renin angiotensin system (RAS) in the context of the oxidative stress-associated liver disease. Areas covered: Angiotensin II (Ang II) as the major effector peptide of the RAS is a pro-oxidant and fibrogenic cytokine. Mechanistically, NADPH oxidase (NOX) is a multicomponent enzyme complex that is able to generate reactive oxygen species (ROS) as a downstream signaling pathway of Ang II which is expressed in liver. Ang II has a detrimental role in the pathogenesis of chronic liver disease through possessing pro-oxidant, fibrogenic, and pro-inflammatory impact in the liver. The alternative axis (ACE2/Ang(1-7)/mas) of the RAS serves as an anti-inflammatory, antioxidant and anti-fibrotic component of the RAS. Expert commentary: In summary, the use of alternative axis inhibitors accompanying with ACE2/ Ang(1-7)/mas axis activation is a promising new strategy serving as a novel therapeutic option to prevent and treat chronic liver diseases.

Keywords: NADPH oxidase; Renin–angiotensin system; angiotensin II; angiotensin converting enzyme inhibitor; angiotensin receptor blocker; anti-oxidant; liver disease; oxidative stress.

Publication types

  • Review

MeSH terms

  • Angiotensin I / metabolism
  • Angiotensin II / metabolism
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme 2
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Antioxidants / adverse effects
  • Antioxidants / therapeutic use*
  • Enzyme Activation
  • Enzyme Activators / therapeutic use
  • Humans
  • Liver / drug effects*
  • Liver / metabolism
  • Liver / physiopathology
  • Liver Diseases / drug therapy*
  • Liver Diseases / metabolism
  • Liver Diseases / physiopathology
  • Molecular Targeted Therapy
  • NADPH Oxidases / metabolism
  • Oxidative Stress / drug effects
  • Peptide Fragments / metabolism
  • Peptidyl-Dipeptidase A / metabolism
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins / agonists
  • Proto-Oncogene Proteins / metabolism
  • Reactive Oxygen Species / metabolism
  • Receptors, G-Protein-Coupled / agonists
  • Receptors, G-Protein-Coupled / metabolism
  • Renin-Angiotensin System / drug effects*
  • Signal Transduction / drug effects
  • Treatment Outcome

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Anti-Inflammatory Agents
  • Antioxidants
  • Enzyme Activators
  • Peptide Fragments
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins
  • Reactive Oxygen Species
  • Receptors, G-Protein-Coupled
  • Angiotensin II
  • Angiotensin I
  • NADPH Oxidases
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2
  • angiotensin I (1-7)